Combating drug-resistant tuberculosis: the unexpected benefits of bedaquiline

被引：3
|
作者：
Furin, Jennifer [1 ]
Diacon, Andreas H. [2 ]
Andries, Koen [3 ]
机构：
[1] Harvard Med Sch, Dept Global Hlth & Social Med, Boston, MA 02115 USA
[2] Univ Stellenbosch, Fac Hlth Sci, Dept Biomed Sci, Tygerberg, South Africa
[3] Janssen Pharmaceut, Infect Dis BVBA, Beerse, Belgium
来源：
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE | 2017年 / 21卷 / 01期
关键词：
D O I：
10.5588/ijtld.16.0768
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：4 / 5
页数：2
相关论文
共 50 条
  • [41] Efficacy of Tuberculosis Treatment in Patients with Drug-Resistant Tuberculosis with the Use of Bedaquiline: The Experience of the Russian Federation
    Starshinova, Anna
    Dovgalyk, Irina
    Belyaeva, Ekaterina
    Glushkova, Anzhela
    Osipov, Nikolay
    Kudlay, Dmitry
    ANTIBIOTICS-BASEL, 2022, 11 (11):
  • [42] Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis
    Schnippel, K.
    Firnhaber, C.
    Page-Shipp, L.
    Sinanovic, E.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2018, 22 (08) : 918 - +
  • [43] Efficacy of bedaquiline in the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis
    Wang, Ming-Gui
    Wu, Shou-Quan
    He, Jian-Qing
    BMC INFECTIOUS DISEASES, 2021, 21 (01)
  • [44] First 2 Extensively Drug-Resistant Tuberculosis Cases From Myanmar Treated With Bedaquiline
    Aung, Htin Lin
    Nyunt, Wint Wint
    Fong, Yang
    Cook, Gregory M.
    Aung, Si Thu
    CLINICAL INFECTIOUS DISEASES, 2017, 65 (03) : 531 - 532
  • [45] Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection
    O'Donnell, Max R.
    Padayatchi, Nesri
    Daftary, Amrita
    Orrell, Catherine
    Dooley, Kelly E.
    Amico, K. Rivet
    Friedland, Gerald
    LANCET HIV, 2019, 6 (03): : E201 - E204
  • [46] Bedaquiline, Delamanid, Linezolid, and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis
    Padmapriyadarsini, Chandrasekaran
    Vohra, Vikram
    Bhatnagar, Anuj
    Solanki, Rajesh
    Sridhar, Rathinam
    Anande, Lalitkumar
    Muthuvijaylakshmi, M.
    Bhatia, Miraa
    Jeyadeepa, Bharathi
    Taneja, Gaurav
    Balaji, S.
    Shah, Prashant
    Saravanan, N.
    Chauhan, Vijay
    Kumar, Hemanth
    Ponnuraja, Chinnayin
    Livchits, Viktoriya
    Bahl, Monica
    Alavadi, Umesh
    Sachdeva, K. S.
    Swaminathan, Soumya
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (03) : E938 - E946
  • [47] Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis
    Maryandyshev, Andrey
    Pontali, Emanuele
    Tiberi, Simon
    Akkerman, Onno
    Ganatra, Shashank
    Sadutshang, Tsetan Dorji
    Alffenaar, Jan-Willem
    Amale, Rohit
    Mullerpattan, Jai
    Topgyal, Sonam
    Udwadia, Zarir Farokh
    Centis, Rosella
    D'Ambrosio, Lia
    Sotgiu, Giovanni
    Migliori, Giovanni Battista
    EMERGING INFECTIOUS DISEASES, 2017, 23 (10) : 1718 - 1721
  • [48] Time to Culture Conversion of Bedaquiline and High-Dose Isoniazid for Drug-Resistant Tuberculosis
    Walsh, Kathleen F.
    Vilbrun, Stalz Charles
    Souroutzidis, Ariadne
    Ellis, Joshua
    Delva, Sobiesyke
    Joissaint, Guy
    Dupnik, Kathryn M.
    Joseph, Patrice
    Pape, Jean W.
    Koenig, Serena P.
    OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (09):
  • [49] Early access to bedaquiline for extensively drug-resistant (XDR) and pre-XDR tuberculosis
    Vasilyeva, Irina
    Mariandyshev, Andrei
    Kazennyy, Boris
    Davidaviciene, Edita
    Lounis, Nacer
    Keim, Sofia
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54 (01)
  • [50] Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine
    Wallis, Robert S.
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48 (05) : 1526 - 1527
12345